FDA accepts Dyne's DMD treatment BLA, grants Priority Review with Jan 2027 target date

Filed July 20, 2026 · Period ending July 20, 2026 · ~1 min read

Key Changes

• high

  FDA accepted BLA for zeleciment rostudirsen (DMD exon 51 skipping treatment), granted Priority Review with Jan 21, 2027 target action date

  Item 8.01 verify on EDGAR →
• high

  Company expects potential U.S. launch in Q1 2027, assuming approval on anticipated timeline

  Item 8.01 verify on EDGAR →